盐酸多柔比星脂质体联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的临床研究  

Clinical Study of Doxorubicin Hydrochloride Liposome Combined with Rituximab in the Treatment of Recurrent and Refractory Non-Hodgkin Lymphoma

作　　者：邱流进 刘轩 肖威 QIU Liujin;LIU Xuan;XIAO Wei(Ganzhou Cancer Hospital,Jiangxi Province,Ganzhou 341000,China;不详)

机构地区：[1]江西省赣州市肿瘤医院,江西赣州341000

出　　处：《中国医学创新》2022年第29期17-20,共4页Medical Innovation of China

基　　金：江西省中医药管理局科技计划项目(2021B539);江西省卫生健康委科技计划项目(202212563)。

摘　　要：目的:探讨盐酸多柔比星脂质体联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤(NHL)的临床效果。方法:根据随机数字表法将2018年1月-2019年12月在赣州市肿瘤医院就诊的168例复发难治性NHL患者分为对照组和试验组,各84例。对照组给予盐酸多柔比星脂质体治疗,试验组给予盐酸多柔比星脂质体联合利妥昔单抗治疗。比较两组患者临床疗效、免疫功能、卡氏评分(KPS评分)及不良反应发生情况。结果:试验组治疗后临床总有效率高于对照组(P<0.05)。两组患者治疗后补体C3、C4均低于治疗前,且试验组均低于对照组(P<0.05)。两组治疗后免疫球蛋白A(IgA)、免疫球蛋白M(IgM)、免疫球蛋白G(IgG)与治疗前比较,差异均无统计学意义(P>0.05),且两组治疗后IgA、IgM、IgG组间比较,差异均无统计学意义(P>0.05)。试验组治疗后KPS评分高于对照组(P<0.05)。试验组治疗期间不良反应总发生率低于对照组(P<0.05)。结论:盐酸多柔比星脂质体联合利妥昔单抗治疗复发难治性NHL患者效果显著,改善生存质量的同时对机体免疫球蛋白无影响,安全性好,具有一定的临床应用价值。Objective:To investigate the clinical efficacy of Doxorubicin Hydrochloride Liposome combined with Rituximab in the treatment of relapsed refractory non-Hodgkin lymphoma(NHL).Method:A total of 168 patients with recurrent and refractory NHL treated in Ganzhou Cancer Hospital from January 2018 to December 2019 were divided into the control group and experimental group according to the random number table method,with 84 cases in each group.The control group was treated with Doxorubicin Hydrochloride Liposome,and the experimental group was treated with Doxorubicin Hydrochloride Liposome combined with Rituximab.The clinical efficacy,immune function,Karnofsky score(KPS score)and adverse reactions were compared between the two groups.Result:The total clinical effective rate in the experimental group after treatment was higher than that in the control group(P<0.05).Complement C3 and C4 in the two groups after treatment were lower than those before treatment, and the experimental group were lower than those of the control group (P<0.05). There were no significant differences in immunoglobulin A (IgA), immunoglobulin M (IgM), and immunoglobulin G (IgG) between the two groups before and after treatment (P>0.05), and there were no significant differences in IgA, IgM and IgG between the two groups after treatment (P>0.05). The KPS score of the experimental group after treatment was higher than that of the control group (P<0.05). The total incidence of adverse reactions in the experimental group during treatment was lower than that in the control group (P<0.05). Conclusion: The combination of Doxorubicin Hydrochloride Liposome and Rituximab in the treatment of recurrent and refractory NHL patients has a significant effect, improves the quality of life and has no impact on the body immunoglobulin, and has a good safety, which has certain clinical application value.

关 键 词：盐酸多柔比星脂质体 利妥昔单抗 复发难治性 非霍奇金淋巴瘤 

分 类 号：R733.1[医药卫生—肿瘤]